DP
SLNO

Diadema Partners’s Soleno Therapeutics SLNO Stock Holding History

Diadema Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,892
Closed -$1.25M – 201
2025
Q4 		$1.25M Sell
26,892
-150,438
-85% -$8.25M 0.21% 85
2025
Q3 		$12M Sell
177,330
-106,822
-38% -$7.92M 3.07% 5
2025
Q2 		$23.8M Buy
284,152
+191,150
+206% +$14.3M 7.25% 1
2025
Q1 		$6.64M Buy
93,002
+21,014
+29% +$1.02M 1.73% 19
2024
Q4 		$3.24M Buy
+71,988
New +$3.73M 1.39% 24

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Diadema Partners's SLNO Position: Q1 2026 in Review

Diadema Partners sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 26,892 shares — an estimated $1.25M sold.

Diadema Partners first reported a position in SLNO in Q4 2024 and held it in 5 quarters. The position peaked at $23.8M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Diadema Partners reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Diadema Partners sold 26,892 Soleno Therapeutics shares in Q1 2026, an estimated $1.25M.
  • Diadema Partners first reported a position in Soleno Therapeutics in Q4 2024 and held it in 5 quarters.
  • Diadema Partners's Soleno Therapeutics position peaked at $23.8M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.